Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension

Bibliography

• Chobanian AV, Bakris GL, Black HR, The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289(19):2560-72
   PubMed Web of Science ®Google Scholar
• Mancia G, De BG, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27(11):2121-58
   PubMed Web of Science ®Google Scholar
• Segura J, Ruilope LM. Are there new threshold and goals in the treatment of arterial hypertension? Eur J Clin Invest 2012;42(8):914-20
   PubMedGoogle Scholar
• Ruddy MC, Kostis JB. Angiotensin II receptor antagonists. In: Oparil S, Weber MA, editors. Hypertension: a companion to brenner and Rector's the kidney. WB Saunders Co; Philadelphia, PA: USA: 2000. p. 621-37
   Google Scholar
• Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - a review. Cardiovasc Diabetol 2009;8:18
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55(2):399-407
   PubMed Web of Science ®Google Scholar
• Stankus V, Hemmelgarn B, Campbell NR, Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009;16(1):e151-5
   PubMedGoogle Scholar
• Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res 2009;37(6):1662-79
   PubMedGoogle Scholar
• White WB, Weber MA, Sica D, Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011;57(3):413-20
   PubMed Web of Science ®Google Scholar
• Galzerano D, Capogrosso C, Di MS, New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010;6:113-33
   PubMedGoogle Scholar
• Littlejohn T, Mroczek W, Marbury T, A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16(9):1123-32
   PubMedGoogle Scholar
• Lacourciere Y, Krzesinski JM, White WB, Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9(4):203-10
   PubMedGoogle Scholar
• Unger T. Preclinical and Clinical Effects of RAS Inhibition With a Focus on Telmisartan. ISRN Vascular Medicine 2012; In press
   Google Scholar
• Takagi H, Yamamoto H, Iwata K, Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol 2012; Epub ahead of print
   Google Scholar
• Takagi H, Umemoto T. Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials. Int J Cardiol 2012;157(3):403-7
   PubMedGoogle Scholar
• Takagi H, Yamamoto H, Iwata K, Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials. Int J Cardiol 2012;156(2):238-41
   PubMedGoogle Scholar
• Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials. Int J Cardiol 2012;156(1):92-6
   PubMedGoogle Scholar
• Takagi H, Umemoto T. Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials. Int J Cardiol 2012;155(3):448-51
   PubMedGoogle Scholar
• Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther 2012;37(3):319-27
   PubMedGoogle Scholar
• Park I, Sheen SS, Lim HS, Comparison of hyperkalemic risk in hospitalized patients treated with different Angiotensin receptor blockers: a retrospective cohort study using a korean clinical research database. Am J Cardiovasc Drugs 2012;12(4):255-62
   PubMed Web of Science ®Google Scholar
• Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011;7:605-22
   PubMedGoogle Scholar
• Yusuf S, Teo KK, Pogue J, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59
   PubMed Web of Science ®Google Scholar
• MicardisPlus Summary of Product Characteristics. 2012. Available from: http://www.ema.europa.eu/ [Last updated 23 January 2012]
   Google Scholar
• McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23(6):833-50
   PubMed Web of Science ®Google Scholar
• Marfatia R, White WB, Schumacher H. Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension. Int J Hypertens 2012;2012:976828
   PubMedGoogle Scholar
• White WB, Punzi HA, Murwin D, Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens (Greenwich) 2006;8(9):626-33
   PubMedGoogle Scholar
• Neldam S, Edwards C. Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich) 2008;10(8):612-18
   PubMedGoogle Scholar
• White WB, Murwin D, Chrysant SG, Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit 2008;13(1):21-7
   PubMed Web of Science ®Google Scholar
• Neldam S, Edwards C. Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication. Expert Opin Pharmacother 2009;10(3):345-52
   PubMed Web of Science ®Google Scholar
• White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Hum Hypertens 2009;23(12):817-25
   PubMedGoogle Scholar
• Lacourciere Y, Tytus R, O'Keefe D, Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001;15(11):763-70
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002;9(2):111-17
   PubMedGoogle Scholar
• Horie Y, Higaki J, Takeuchi M. Design, statistical analysis and sample size calculation of dose response study of telmisartan and hydrochlorothiazide. Contemp Clin Trials 2007;28(5):647-53
   PubMedGoogle Scholar
• Zhu DL, Bays H, Gao P, Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial. Clin Ther 2012;34(7):1613-24
   PubMedGoogle Scholar
• Neldam S, Schumacher H, Guthrie R. Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures. Adv Ther 2012;129(4):327-38
   Google Scholar
• Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008;1:32-40
   PubMedGoogle Scholar
• Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich) 2011;13(9):677-86
   PubMedGoogle Scholar
• Lacourciere Y, Gil-Extremera B, Mueller O, Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003;57(4):273-9
   PubMedGoogle Scholar
• Neutel JM, Littlejohn TW, Chrysant SG, Singh A. Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005;28(7):555-63
   PubMedGoogle Scholar
• Lacourciere Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005;27(11):1795-805
   PubMedGoogle Scholar
• Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007;6:28
   PubMed Web of Science ®Google Scholar
• Rump LC, Ambrosioni E, Burnier M, Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006;20(4):299-301
   PubMedGoogle Scholar
• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303(20):2043-50
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20(1):72-80
   PubMed Web of Science ®Google Scholar
• Corrao G, Zambon A, Parodi A, Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26(4):819-24
   PubMed Web of Science ®Google Scholar
• Song JC, White MC. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001;36:487-99
   Google Scholar
• Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002;16(Suppl 2):S13-16
   PubMedGoogle Scholar
• Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25(1):41-6
   PubMedGoogle Scholar
• Plosker GL, White WB. Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. Drugs 2008;68(13):1877-99
   PubMedGoogle Scholar
• Neutel JM. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr Med Res Opin 2010;26(1):213-22
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Gentile G, Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011;4(2):151-61
   PubMedGoogle Scholar
• Ruilope LM. Telmisartan for the management of patients at high cardiovascular risk. Curr Med Res Opin 2011;27(8):1673-82
   PubMed Web of Science ®Google Scholar
• Garg JP, Elliott WJ, Folker A, Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18(5 Pt 1):619-26
   PubMedGoogle Scholar
• Calhoun DA, Jones D, Textor S, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117(25):e510-26
   PubMed Web of Science ®Google Scholar